Derecho a la Vida Privada en las Negociaciones del TPP

La Oficina del Representante Comercial de los Estados Unidos (USTR) ha declarado su intención de tener completadas sus propuestas sobre protección de la propiedad intelectual a comienzos de la próxima ronda de negociaciones del TPP en Vietnam, del 20 al 24 de junio de 2011. En su rápida agenda, los negociadores del TPP han anunciado que ellos esperan concluir el acuerdo para el encuentro de los miembros del Foro de Cooperación Económica Asia-Pacífico, a realizarse en Hawaii del 8 al 13 de noviembre de 2011. Continue Reading

Uncategorized

Right to Privacy in Trans-Pacific Partnership (TPP ) Negotiations

The Office of the U.S. Trade Representative (USTR) has declared an intention to have all its proposals on intellectual property protections by the commencement of the next round of TPP talks in Vietnam June 20-24, 2011. On a fast timetable, TPP negotiators have already announced that they want to finalize TPP by the summit meetings of the members of the Asia-Pacific Economic Cooperation on November 8-13, 2011 in Hawaii. The TPP will impact health, access to knowledge, and without the necessary safeguards, the right to privacy.

Continue Reading

Uncategorized

Opening statement of Uruguay at WIPO’s 22nd Standing Committee on Copyright and Related Rights

Comité Permanente de Derechos de Autor y Conexos – SCCR 22 – OMPI – Ginebra
Intervención de la Delegación de Uruguay. Ginebra, 15 de junio de 2011.

Gracias Señor Presidente,

Señor Presidente, reciba de nuestra delegación nuestras mas sinceras felicitaciones por su designación como Presidente del Comité Permanente de Derechos de Autor y Conexos SCCR y cuente con nuestro apoyo para hacer una exitosa gestión al frente de este importante comité.

Señor Presidente:

Continue Reading

Uncategorized

FDA New drug approvals for 2011, through June 6

This is a report from the FDA on 2011 new molecular entities (NMEs) approvals, through June 6, 2011. The total number of FDA approvals during that same period was 150. So far, 16 NMEs have been approved in five months, a sharp increase in approvals over the same period 2010.

6 NMEs NDAs were considered priorities
8 NDAs that were considered standard approvals
2 BLA (biologic products) that were not classified.

  • NMEs were 10.7 percent of all approvals.
  • The NME priority NDAs were 4 percent of FDA approvals.
  • Continue Reading

Uncategorized